

Extensive-Stage Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/E47299C08890EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: E47299C08890EN

Abstracts

The 7 major extensive-stage small cell lung cancer markets are expected to exhibit a CAGR of 7.6% during 2024-2034.

The extensive-stage small cell lung cancer market has been comprehensively analyzed in IMARC's new report titled "Extensive-Stage Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Extensive-stage small cell lung cancer is an advanced form of lung cancer in which the cancer has spread beyond the lung to distant sites in the body. It is characterized by the presence of cancerous cells in multiple areas of the lung, lymph nodes on the opposite side of the chest, or various other organs, such as the liver, bones, brain, etc. Some of the common symptoms include persistent cough, shortness of breath, chest pain, fatigue, unintentional weight loss, loss of appetite, hoarseness, difficulty swallowing, swollen lymph nodes, bone pain, headaches, seizures, etc. Diagnosing extensive-stage small cell lung cancer involves a combination of clinical evaluations, imaging tests, and laboratory analyses. The process typically begins with a comprehensive medical history and physical examination. To confirm the diagnosis and determine the stage of cancer, numerous imaging procedures, such as computed tomography (CT) scans, positron emission tomography (PET) scans, magnetic resonance imaging (MRI), etc., may be performed. Additionally, a biopsy is often conducted to obtain a sample of the lung tissue or other affected areas for microscopic examination and testing.

The increasing cases of exposure to cigarette smoke, which contains numerous carcinogens that can damage the DNA in lung cells, thereby leading to the development of cancerous cells, are primarily driving the extensive-stage small cell lung cancer

market. In addition to this, the inflating application of immune checkpoint inhibitors, such as pembrolizumab or nivolumab, which work by unleashing the body's immune system to recognize and attack cancer cells, is acting as another significant growth-inducing factor. Moreover, the widespread adoption of CAR-T cell therapy, since it uses genetically modified T cells to eliminate cancer cells and achieve long-term remission while alleviating treatment-related toxicity, is further creating a positive outlook for the market. Apart from this, the emerging popularity of prophylactic cranial irradiation therapy on account of its several associated benefits, such as reduction in the incidence of brain metastases, prevention of neurological symptoms, and preservation of cognitive function, is also bolstering the market growth. Furthermore, the escalating demand for liquid biopsies that aid in real-time monitoring of tumor dynamics and early detection of resistance mutations is expected to drive the extensive-stage small cell lung cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the extensive-stage small cell lung cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for extensive-stage small cell lung cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the extensive-stage small cell lung cancer market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the extensive-stage small cell lung cancer market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the extensive-stage small cell lung cancer market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current extensive-stage small cell lung cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Extensive-Stage Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity...

Market Insights

How has the extensive-stage small cell lung cancer market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the extensive-stage small cell lung cancer market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the extensive-stage small cell lung cancer market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of extensive-stage small cell lung cancer across the seven major markets?

What is the number of prevalent cases (2018-2034) of extensive-stage small cell lung cancer by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of extensive-stage small cell lung cancer by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with extensive-stage small cell lung cancer across the seven major markets?

What is the size of the extensive-stage small cell lung cancer patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of extensive-stage small cell lung cancer?

What will be the growth rate of patients across the seven major markets?

Extensive-Stage Small Cell Lung Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for extensive-stage small cell lung cancer

drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the extensive-stage small cell lung cancer market?

What are the key regulatory events related to the extensive-stage small cell lung cancer market?

What is the structure of clinical trial landscape by status related to the extensive-stage small cell lung cancer market?

What is the structure of clinical trial landscape by phase related to the extensive-stage small cell lung cancer market?

What is the structure of clinical trial landscape by route of administration related to the extensive-stage small cell lung cancer market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - UNMET NEEDS

10 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - KEY ENDPOINTS OF TREATMENT

11 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - MARKETING PRODUCTS

- 11.1 List of Extensive-Stage Small Cell Lung Cancer Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Imfinzi (Durvalumab) - AstraZeneca
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - PIPELINE DRUGS

12.1 List of Extensive-Stage Small Cell Lung Cancer Pipeline Drugs Across the Top 7 Markets

12.1.1 Ifinatamab deruxtecan - Daiichi Sankyo Company

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. EXTENSIVE-STAGE SMALL CELL LUNG CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETING AND PIPELINE DRUGS

14. EXTENSIVE-STAGE SMALL CELL LUNG CANCER – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Extensive-Stage Small Cell Lung Cancer - Access and Reimbursement

Overview

15.4 Market Scenario - Germany

15.4.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

15.4.3 Extensive-Stage Small Cell Lung Cancer - Access and Reimbursement

Overview

15.5 Market Scenario - France

15.5.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.5.1.1 Market Size (2018-2023)

15.5.1.2 Market Forecast (2024-2034)

15.5.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.5.2.1 Market Size by Therapies (2018-2023)

15.5.2.2 Market Forecast by Therapies (2024-2034)

15.5.3 Extensive-Stage Small Cell Lung Cancer - Access and Reimbursement

Overview

15.6 Market Scenario - United Kingdom

15.6.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.6.1.1 Market Size (2018-2023)

15.6.1.2 Market Forecast (2024-2034)

15.6.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.6.2.1 Market Size by Therapies (2018-2023)

15.6.2.2 Market Forecast by Therapies (2024-2034)

15.6.3 Extensive-Stage Small Cell Lung Cancer - Access and Reimbursement

Overview

15.7 Market Scenario - Italy

15.7.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.7.1.1 Market Size (2018-2023)

15.7.1.2 Market Forecast (2024-2034)

15.7.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.7.2.1 Market Size by Therapies (2018-2023)

15.7.2.2 Market Forecast by Therapies (2024-2034)

15.7.3 Extensive-Stage Small Cell Lung Cancer - Access and Reimbursement

Overview

15.8 Market Scenario - Spain

15.8.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.8.1.1 Market Size (2018-2023)

15.8.1.2 Market Forecast (2024-2034)

15.8.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.8.2.1 Market Size by Therapies (2018-2023)

15.8.2.2 Market Forecast by Therapies (2024-2034)

15.8.3 Extensive-Stage Small Cell Lung Cancer - Access and Reimbursement

Overview

15.9 Market Scenario - Japan

15.9.1 Extensive-Stage Small Cell Lung Cancer - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034)

15.9.2 Extensive-Stage Small Cell Lung Cancer - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Extensive-Stage Small Cell Lung Cancer - Access and Reimbursement

Overview

16 EXTENSIVE-STAGE SMALL CELL LUNG CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 EXTENSIVE-STAGE SMALL CELL LUNG CANCER MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 EXTENSIVE-STAGE SMALL CELL LUNG CANCER MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Extensive-Stage Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/E47299C08890EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E47299C08890EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

